Gonorrhoea, a sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, remains a major public health threat ...

Gonorrhea is an STI similar to chlamydia caused by the bacterium Neisseria gonorrheoae. It is passed in the same way as chlamydia, with symptoms in the urethra, rectum, and throat usually appearing ...

Common symptoms include intense urges to pee, burning sensations, peeing more often, and pain in the lower stomach. Staying well-hydrated and eating antioxidant-rich foods can help relieve UTI ...

Findings from the APPEAR-C3G trial showed a 35% reduction in 24-hour UPCR from baseline (primary endpoint) in the iptacopan group compared with the placebo group. The Food and Drug Administration ...

If successful, it could become a multi-purpose treatment option in the fight against resistant bacterial infections. The approval of Blujepa marks a major breakthrough in UTI treatment ...

PARIS, April 01, 2025 (GLOBE NEWSWIRE) -- Sysmex’s PA-100 AST System is redefining standard of care for diagnosing and treating urinary tract infections ... transforms the treatment of UTIs.

Common symptoms of a urinary tract infection (UTI)—like frequent urination and pain in the lower abdomen—can sometimes make it difficult to sleep at night. If you have a UTI, there are home remedies ...

Providing clinicians with rapid and precise diagnostic insights transforms the treatment of UTIs. It benefits patients and strengthens healthcare systems' financial sustainability. Recent budget ...

Whether you’re looking for a daily supplement or a fast-acting treatment for a current UTI, we’ve got you covered. CranEaze®: Cranberry Juice Extract Plus D-Mannose – 36 mg PAC, 100% ...

NHS bosses are urging people to "stay home" if they experience any or both of two nasty symptoms. It comes as norovirus cases remain extremely high across England. The illness, while unpleasant ...

Developed by GlaxoSmithKline (GSK), this antibiotic represents the first new oral treatment for UTIs in nearly ... a commonly prescribed UTI antibiotic. EAGLE-2 Trial: 50.6% of patients treated ...